Johnston Erwin, TRexBio CEO
November 13, 2024 07:00 AM EST
Financing

TRexBio rais­es $84M to take in-house im­mune pro­gram in­to the clin­ic

Lei Lei Wu

News Reporter

Bay Area im­munol­o­gy biotech TRexBio has raised a $84 mil­lion Se­ries B to start clin­i­cal stud­ies of a po­ten­tial treat­ment for atopic der­mati­tis and ul­cer­a­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times